keyword
MENU ▼
Read by QxMD icon Read
search

Non alcoholic steatohepatitis

keyword
https://www.readbyqxmd.com/read/29231919/-non-alcoholic-liver-disease-diagnosis-and-treatment
#1
REVIEW
Anna Sarosiekjeznach-Steinhagen, Joanna Ostrowska, Aneta Czerwonogrodzka-Senczyna, Iwona Boniecka
Non-alcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease in the developed world (15% to 40% of the adult population). Introduction of lifestyle changes including dietary intervention and increased physical activity is most often the first-line treatment and is intended to support not only the treatment of liver disease, but also for diseases associated with obesity, insulin resistance, diabetes and dyslipidemia. In addition to well-known metformin, there are new classes of antidiabetic drugs, including GLP-1analog, SGLT-2 antagonist, pioglitazon...
November 23, 2017: Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/29229391/hepatocyte-specific-clusterin-overexpression-attenuates-diet-induced-nonalcoholic-steatohepatitis
#2
Jin-Sung Park, Young-Jun Shim, Byeong-Ho Kang, Woon-Kyu Lee, Bon-Hong Min
Clusterin is a multifunctional glycoprotein that plays important roles and is up-regulated in liver diseases such as hepatitis and hepatocellular carcinoma. However, little is known about the significance of clusterin in the pathogenesis of non-alcoholic steatohepatitis (NASH). The aim of this study is to examine the role of clusterin in progression of steatohepatitis in mice fed a methionine and choline deficient (MCD) diet. We generated hepatocyte-specific clusterin overexpression (hCLU-tg) mice, and hCLU-tg mice showed lower levels of hepatic triglycerides, less infiltration of macrophages and reduction of TNF-α, activation of Nrf-2 than wild-type littermates fed the MCD diet...
December 8, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29224910/regulation-of-sirt3-foxo1-signaling-pathway-in-rats-with-non-alcoholic-steatohepatitis-by-salvianolic-acid-b
#3
Yingchun Wang, Juan Chen, Weizong Kong, Ruiping Zhu, Kai Liang, Quanxiang Kan, Yanhong Lou, Xiangyu Liu
AIMS: To explore the effect of salvianolic acid B (Sal B) on regulation of SIRT3/FOXO1 signaling pathway in rats with non-alcoholic steatohepatitis (NASH). METHODS: Sixty Sprague Dawley (SD) rats were randomly divided into control, model and treatment groups. After 12 weeks of successful model establishment with high fat diet, treatment group was given Sal B by intragastric administration. After 12 weeks of treatment, rats were sacrificed and livers were taken to test indicators such as liver index, TG, TC, ALT, AST, reactive oxygen species (ROS) by DCFH-DA probe, SOD2 activity by WST-8 test...
December 7, 2017: Archives of Medical Research
https://www.readbyqxmd.com/read/29223443/response-to-pioglitazone-in-patients-with-nonalcoholic-steatohepatitis-with-vs-without-type-2-diabetes
#4
Fernando Bril, Srilaxmi Kalavalapalli, Virginia C Clark, Romina Lomonaco, Consuelo Soldevila-Pico, I-Chia Liu, Beverly Orsak, Fermin Tio, Kenneth Cusi
BACKGROUND & AIMS: Pioglitazone is effective for long-term treatment of patients with nonalcoholic steatohepatitis (NASH) with prediabetes or type-2 diabetes. However, it is not clear how the presence of type-2 diabetes affects the drug's efficacy. We compared metabolic and histologic responses to pioglitazone in patients with NASH and prediabetes vs type-2 diabetes. METHODS: We performed a prospective study of adults with biopsy-proven NASH (52 with type-2 diabetes and 49 with prediabetes), enrolled from the general population of San Antonio, Texas from 2008 through 2014...
December 6, 2017: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29223369/a-critical-review-of-endpoints-for-non-cirrhotic-nash-therapeutic-trials
#5
REVIEW
Vlad Ratziu
Non-alcoholic steatohepatitis is a disease without a single, specific, diagnostic marker, hence multiple indicators are required to measure therapeutic efficacy. Moreover, drug candidates for non-alcoholic steatohepatitis target many distinct mechanisms that are believed to promote hepatic injury. Therefore, a wide range of endpoints must be reached, sequentially, as required by the drug development process. Some of these endpoints validate the mechanism of action, others are used to anticipate histological efficacy...
December 6, 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/29222917/diagnostic-modalities-for-non-alcoholic-fatty-liver-disease-nafld-non-alcoholic-steatohepatitis-nash-and-associated-fibrosis
#6
REVIEW
Zobair M Younossi, Rohit Loomba, Quentin M Anstee, Mary E Rinella, Elisabetta Bugianesi, Giulio Marchesini, Brent A Neuschwander-Tetri, Lawrence Serfaty, Francesco Negro, Stephen H Caldwell, Vlad Ratziu, Kathleen E Corey, Scott L Friedman, Manal F Abdelmalek, Stephen A Harrison, Arun J Sanyal, Joel E Lavine, Philippe Mathurin, Michael R Charlton, Zachary D Goodman, Naga P Chalasani, Kris V Kowdley, Jacob George, Keith Lindor
NAFLD is a spectrum comprised of isolated steatosis, NASH, advanced fibrosis, and cirrhosis. The majority of NAFLD subjects do not have NASH and don't carry a significant risk for adverse outcomes (cirrhosis and mortality). Globally, the prevalence of NAFLD is approximately 25%. In Asia, a gradient of high prevalence rates to low rates are noted from urban to rural areas. Given the prevalence of NAFLD, the clinical and economic burden of NAFLD and NASH can be substantial. With increasing recognition as an important liver disease, the diagnosis of NASH still requires a liver biopsy which is suboptimal...
December 9, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29222911/current-and-future-therapeutic-regimens-for-non-alcoholic-fatty-liver-disease-nafld-and-non-alcoholic-steatohepatitis-nash
#7
REVIEW
Zobair M Younossi, Rohit Loomba, Mary E Rinella, Elisabetta Bugianesi, Giulio Marchesini, Brent A Neuschwander-Tetri, Lawrence Serfaty, Francesco Negro, Stephen H Caldwell, Vlad Ratziu, Kathleen E Corey, Scott L Friedman, Manal F Abdelmalek, Stephen A Harrison, Arun J Sanyal, Joel E Lavine, Philippe Mathurin, Michael R Charlton, Naga P Chalasani, Quentin M Anstee, Kris V Kowdley, Jacob George, Zachary D Goodman, Keith Lindor
NASH/NAFLD is rapidly becoming one of top causes of cirrhosis, hepatocellular carcinoma and indication for liver transplantation. Except for life style modification through diet and exercise, there are currently no other approved treatments for NASH/NAFLD. Although weight loss can be effective, it is hard to achieve and sustain. In contrast, bariatric surgery can improve metabolic conditions associated with NAFLD and has been shown to improve liver histology. In order to have approved regimens for treatment of NASH/NAFLD, a number of issues that must be addressed...
December 9, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/29220698/synergistic-interaction-of-fatty-acids-and-oxysterols-impairs-mitochondrial-function-and-limits-liver-adaptation-during-nafld-progression
#8
Francesco Bellanti, Rosanna Villani, Rosanna Tamborra, Maria Blonda, Giuseppina Iannelli, Giorgia di Bello, Antonio Facciorusso, Giuseppe Poli, Luigi Iuliano, Carlo Avolio, Gianluigi Vendemiale, Gaetano Serviddio
The complete mechanism accounting for the progression from simple steatosis to steatohepatitis in nonalcoholic fatty liver disease (NAFLD) has not been elucidated. Lipotoxicity refers to cellular injury caused by hepatic free fatty acids (FFAs) and cholesterol accumulation. Excess cholesterol autoxidizes to oxysterols during oxidative stress conditions. We hypothesize that interaction of FAs and cholesterol derivatives may primarily impair mitochondrial function and affect biogenesis adaptation during NAFLD progression...
December 5, 2017: Redox Biology
https://www.readbyqxmd.com/read/29216278/systematic-integrative-analysis-of-gene-expression-identifies-hnf4a-as-the-central-gene-in-pathogenesis-of-non-alcoholic-steatohepatitis
#9
Cristina Baciu, Elisa Pasini, Marc Angeli, Katherine Schwenger, Jenifar Afrin, Atul Humar, Sandra Fischer, Keyur Patel, Johane Allard, Mamatha Bhat
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the Western world, and encompasses a spectrum from simple steatosis to steatohepatitis (NASH). There is currently no approved pharmacologic therapy against NASH, partly due to an incomplete understanding of its molecular basis. The goal of this study was to determine the key differentially expressed genes (DEGs), as well as those genes and pathways central to its pathogenesis. We performed an integrative computational analysis of publicly available gene expression data in NASH from GEO (GSE17470, GSE24807, GSE37031, GSE89632)...
2017: PloS One
https://www.readbyqxmd.com/read/29215054/in-vivo-redox-metabolic-imaging-of-mitochondria-assesses-disease-progression-in-non-alcoholic-steatohepatitis
#10
Ryosuke Nakata, Fuminori Hyodo, Masaharu Murata, Hinako Eto, Tomoko Nakaji, Takahito Kawano, Sayoko Narahara, Keiji Yasukawa, Tomohiko Akahoshi, Morimasa Tomikawa, Makoto Hashizume
Given the rising incidence of non-alcoholic fatty liver disease (NAFLD) in both adults and children, the development of a non-invasive diagnostic method for assessing disease progression to non-alcoholic steatohepatitis (NASH) has become an important research goal. Currently available non-invasive imaging technologies are only able to assess fat accumulation in the liver. Therefore, these methods are not suitable for a precise diagnosis of NASH. The standard diagnostic technique for NASH, liver biopsy, has several drawbacks, including the higher risk of complications that accompanies invasive procedures...
December 7, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29214510/myeloid-deficiency-of-ccn3-exacerbates-liver-injury-in-a-mouse-model-of-nonalcoholic-fatty-liver-disease
#11
Wenconghui Wu, Xingjian Hu, Xianming Zhou, Philip A Klenotic, Qi Zhou, Zhiyong Lin
Non-alcoholic fatty liver disease (NAFLD) is a condition in which fat accumulates in the liver of patients without a prior history of alcohol abuse. The most severe form, nonalcoholic steatohepatitis (NASH), often leads to hepatic fibrosis and cirrhosis with ensuing complications. To date, there is no pharmacologic treatment for NASH. The biological effects of CCN3, specifically its role in the regulation of inflammation, reactive oxygen species production and angiogenesis, have been recently established. Additional data suggests that CCN3 is associated with the development of tumors in the liver yet may be protective of liver fibrogenesis...
December 6, 2017: Journal of Cell Communication and Signaling
https://www.readbyqxmd.com/read/29212576/the-effects-of-physical-exercise-on-fatty-liver-disease
#12
Dirk J van der Windt, Vikas Sud, Hongji Zhang, Allan Tsung, Hai Huang
The increasing prevalence of obesity has made non-alcoholic fatty liver disease (NAFLD) the most common chronic liver disease. As a consequence, NAFLD and especially its inflammatory form non-alcoholic steatohepatitis (NASH) are the fastest increasing etiology of end-stage liver disease and hepatocellular carcinoma. Physical inactivity is related to the severity of fatty liver disease irrespective of body weight, supporting the hypothesis that increasing physical activity through exercise can improve fatty liver disease...
December 6, 2017: Gene Expression
https://www.readbyqxmd.com/read/29210655/editorial-recent-news-on-statins-for-the-treatment-of-non-alcoholic-fatty-liver-disease-non-alcoholic-steatohepatitis
#13
EDITORIAL
Vasilios G Athyros, Niki Katsiki, Michael Doumas
No abstract text is available yet for this article.
December 4, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/29204050/current-and-emerging-pharmacological-therapy-for-non-alcoholic-fatty-liver-disease
#14
EDITORIAL
Ahad Eshraghian
The main treatment of patients with non-alcoholic fatty liver disease (NAFLD) is life style modification including weight reduction and dietary regimen. Majority of patients are safely treated with this management and pharmacologic interventions are not recommended. However, a subgroup of NAFLD patients with non-alcoholic steatohepatitis (NASH) who cannot achieve goals of life style modification may need pharmacological therapy. One major obstacle is measurement of histological outcome by liver biopsy which is an invasive method and is not recommended routinely in these patients...
November 14, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/29203247/co-administration-of-apd668-a-g-protein-coupled-receptor-119-agonist-and-linagliptin-a-dppiv-inhibitor-prevents-progression-of-steatohepatitis-in-mice-fed-on-a-high-trans-fat-diet
#15
Umakant Ashok Bahirat, Rekha Raghuveer Shenoy, Rashmi Talwar, Rajan Naresh Goel, Kumar V S Nemmani
Non-Alcoholic SteatoHepatitis (NASH) is the more severe form of Non-Alcoholic Fatty Liver Disease (NAFLD) and is characterized by the presence of hepatic steatosis, oxidative stress, inflammation, hepatocyte injury with or without fibrosis. Recently, GPR119 receptor has emerged as a novel therapeutic target for the treatment of dyslipidemia and non-alcoholic steatohepatitis. In the present study, we investigated the effect of APD668, a GPR119 agonist alone or in combination with linagliptin, a DPPIV inhibitor on the progression of steatohepatitis in mice fed on a high trans-fat diet...
December 1, 2017: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/29202557/non-alcoholic-fatty-liver-disease-and-lifestyle-modifications-focusing-on-physical-activity
#16
Min-Sun Kwak, Donghee Kim
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease, and the prevalence of non-alcoholic steatohepatitis (NASH) with fibrosis is increasing as the population with NAFLD ages. To date, lifestyle modifications including weight loss, increased physical activity, and dietary changes remain the treatment of choice for NAFLD because there are no approved effective pharmacologic agents. Increased physical activity has therapeutic effects on NAFLD by reducing hepatic fat independent of weight reduction...
December 6, 2017: Korean Journal of Internal Medicine
https://www.readbyqxmd.com/read/29201174/effects-of-activated-carbon-n-acetylcysteine-sustained-release-microcapsule-on-dipeptidyl-peptidase-iv-expression-in-young-rats-with-non-alcoholic-fatty-liver-disease
#17
Hongping Zhou, Tingting Shi, Jun Yan, Xiaojin Chen, Li Liao, Shiyong Zhao, Hongying Fang, Rangxiao Zhuang
Non-alcoholic fatty liver disease (NAFLD) in children has become the most common liver disease influencing adolescent health and one of the most influencing chronic liver diseases among children in Chinese wealthy families, particularly in coastal regions. However, the medicine available for the treatment of NAFLD is deficient. In order to solve this problem, our team studied the activated carbon N-acetylcysteine (NAC) sustained-release microcapsule, which improves the oxidation resistance, bioavailability and drug stability of acetylcysteine and reduces toxic and side effects...
November 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/29199410/non-alcoholic-fatty-liver-disease-the-emerging-burden-in-cardiometabolic-and-renal-diseases
#18
REVIEW
Eugene Han, Yong Ho Lee
As the number of individuals with non-alcoholic fatty liver disease (NAFLD) has increased, the influence of NAFLD on other metabolic diseases has been highlighted. Accumulating epidemiologic evidence indicates that NAFLD not only affects the liver but also increases the risk of extra-hepatic diseases such as type 2 diabetes mellitus, metabolic syndrome, dyslipidemia, hypertension, cardiovascular or cerebrovascular diseases, and chronic kidney disease. Non-alcoholic steatohepatitis, an advanced type of NAFLD, can aggravate these inter-organ relationships and lead to poorer outcomes...
November 17, 2017: Diabetes & Metabolism Journal
https://www.readbyqxmd.com/read/29197627/mir-34a-regulates-mitochondrial-content-and-fat-ectopic-deposition-induced-by-resistin-through-the-ampk-ppar%C3%AE-pathway-in-hepg2-cells
#19
Fengyun Wen, Chaoqing An, Xiaotian Wu, Yi Yang, Jingjing Xu, Yasong Liu, Chunming Wang, Leitong Nie, Hubin Fang, Zaiqing Yang
Resistin is an adipocyte-derived cytokine and was named for its role in the development of insulin resistance. Increased serum resistin levels are also associated with steatohepatitis and non-alcoholic fatty liver disease. In a previous study, resistin was observed to reduce mitochondrial content and upregulate miR-34a significantly in the liver. In this study, male C57BL/6 mice were injected with agomir-34a or control agomir, and HepG2 cells were transfected with miR-34a mimics or inhibitors to assess their role in resistin-induced fat deposition...
November 29, 2017: International Journal of Biochemistry & Cell Biology
https://www.readbyqxmd.com/read/29197393/association-of-serum-ferritin-with-non-alcoholic-fatty-liver-disease-a-meta-analysis
#20
Shui-Xian Du, Lin-Lin Lu, Ning Geng, David W Victor, Li-Zhen Chen, Cong Wang, Hai-Yan Yue, Yong-Ning Xin, Shi-Ying Xuan, Wen-Wen Jin
BACKGROUND: A growing number of studies reported the connection between the level of serum ferritin (SFL) and non-alcoholic fatty liver disease (NAFLD). However, such connection was still disputable. The aim of our meta-analysis was to estimate SFL between the groups as below: patients with NAFLD against control group; non-alcoholic steatohepatitis (NASH) patients against control group; non-alcoholic fatty liver (NAFL) patients against a control group and NASH patients vs NAFL patients...
December 2, 2017: Lipids in Health and Disease
keyword
keyword
41965
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"